VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia

References

• Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.
   PubMed Web of Science ®Google Scholar
• Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65:8912–9.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.
   PubMed Web of Science ®Google Scholar
• Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, et al. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci USA. 2009;106:3378–83.
   PubMed Web of Science ®Google Scholar
• Yin T, Wu YL, Sun HP, Du YZ, Wang KK, Zhang J, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol. 2002;39(2 Suppl 1):22–6.
   Web of Science ®Google Scholar
• Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000;95:1014–22.
   PubMed Web of Science ®Google Scholar
• Konig H, Härtel N, Schultheis B, Schatz M, Lorentz C, Melo JV, et al. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. Haematologica. 2007;92(6):838–41.
   PubMed Web of Science ®Google Scholar
• La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib resistant Bcr-Abl-positive cell lines. Blood. 2004;103(1):208–15.
   Google Scholar
• Sun HD, Ma L, Hu XC, Zhang TD. Ai-lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med. 1992;12:170–1.
   Google Scholar
• Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106(9):3342–7.
   PubMed Web of Science ®Google Scholar
• Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37:1035–42.
   PubMed Web of Science ®Google Scholar
• Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175–85.
   PubMed Web of Science ®Google Scholar
• Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget. 2011;2(12):1322–8.
   PubMedGoogle Scholar
• Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002;100(10):3767–75.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program. 2011;2011:1–8.
   PubMedGoogle Scholar
• Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of VEGF and its receptor in hematopoietic malignancies. Cancer Res. 1999;59:728–33.
   PubMed Web of Science ®Google Scholar
• Dias S, Hattori K, Zhou Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106:511–21.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94(11):3717–21.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99(6):2265–7.
   PubMed Web of Science ®Google Scholar
• Molica S, Vitell G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum level of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer. 2002;86(1):31–5.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2002;68(2):91–100.
   PubMed Web of Science ®Google Scholar
• Fei J, Zhang Y. Prediction of VEGF mRNA antisense oligodeoxynucleotides by RNA structure software and their effects on HL60 and K562 cells. Cell Biol Int. 2005;29(9):737–41.
   PubMed Web of Science ®Google Scholar
• Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp9 mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2002;99:2532–40.
   PubMed Web of Science ®Google Scholar
• Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4(VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99(6):2179–84.
   PubMed Web of Science ®Google Scholar
• Kautoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M, et al. VEGF inhibits apoptotic cell death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res. 1998;58:5565–9.
   PubMed Web of Science ®Google Scholar
• Kuramoto K, Uesaka T, Kimura A, Kobayashi M, Watanabe H, Katoh O. ZK7, a novel zinc finger gene, is induced by vascular endothelial growth factor and inhibits apoptotic death in hematopoietic cell. Cancer Res. 2000;60:425–30.
   PubMed Web of Science ®Google Scholar
• Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA. 2001;98(19):10857–62.
   PubMed Web of Science ®Google Scholar
• Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 2012;120(17):3555–62.
   PubMed Web of Science ®Google Scholar
• Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 2003;63:7081–8.
   PubMed Web of Science ®Google Scholar
• Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003;1:66.
   PubMedGoogle Scholar
• Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, et al. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione s-transferase p1–1. Clin Cancer Res. 2012;18(24):6690–701.
   PubMed Web of Science ®Google Scholar
• Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods. 2008;44(1):55–60.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–7.
   PubMed Web of Science ®Google Scholar